


WWW.PROBECHEM.COM

Data Sheet

Global Supplier of Chemical Probes, Inhibitors & Agonists.

Product Name	:	Linperlisib
Cat. No.	:	PC-23166
CAS No.	:	1702816-75-8
Molecular Formula	:	C ₂₈ H ₃₇ FN ₆ O ₅ S
Molecular Weight	:	588.70
Target	:	PI3K
Solubility	:	10 mM in DMSO



Biological Activity

Linperlisib (YY-20394) is a potent, selective and orally active **PI3K8** inhibitor (IC50=4.6 nM), inhibitr PI3K8 expressing human tumor cells growth both in vitro and in vivo.

Linperlisib (YY-20394) is less activity against PI3K γ giving a kinase inhibition profile that is more PI3K δ -selective by nearly 2 orders of magnitude

Linperlisib (YY-20394) significantly inhibited primary tumor growth in immune-competent mice with 4T1 and CT26 tumors, as well as 4T1 lung metastasis with dose dependency.

The anti-tumor efficacy of YY-20394 was largely mediated by T cells.

Linperlisib (YY-20394) synergistically enhanced the anti-tumor efficacy of anti-PD-L1 antibody in CT26 model and achieved long-term immune memory which is specific for CT26 tumors, but not for unrelated A20 tumors.

Linperlisib (YY-20394) significantly inhibited T cell differentiation into Treg both in mouse splenocyte and in human primary CD4+ T cells, and was especially potent inhibiting their IL-10 secretion in vitro.

Linperlisib (YY-20394) displayed significant anti-tumor efficacy in other syngeneic mouse tumor models tested including mouse colorectal cancer models MC-38 model in C57BL/c mice and CT26 model in BALB/c mice.

References

Wang T, et al. Clin Cancer Res. 2023 Apr 14;29(8):1440-1449.

Jiang B, et al. J Hematol Oncol. 2021 Aug 23;14(1):130.

ZuSheng Xu, et al. Cancer Immunol Res (2016) 4 (11_Supplement): B048.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com